Posted by Michael Wonder on 02 Feb 2023
Tezspire approved for self-administration in the US with a new pre-filled pen
2 February 2023 - First and only respiratory biologic without phenotype or biomarker limitations that offers the choice of administration at home or in a doctor’s office
AstraZeneca and Amgen’s Tezspire (tezepelumab) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.
